BioSyent Inc. (BIOYF)
OTCMKTS
· Delayed Price · Currency is USD
7.56
-0.29 (-3.69%)
Jan 14, 2025, 4:00 PM EST
BioSyent Revenue
BioSyent had revenue of 9.56M CAD in the quarter ending September 30, 2024, with 7.72% growth. This brings the company's revenue in the last twelve months to 34.51M, up 12.12% year-over-year. In the year 2023, BioSyent had annual revenue of 31.59M with 13.12% growth.
Revenue (ttm)
34.51M CAD
Revenue Growth
+12.12%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
86.00M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 31.59M | 3.67M | 13.12% |
Dec 31, 2022 | 27.93M | -693.03K | -2.42% |
Dec 31, 2021 | 28.62M | 6.29M | 28.15% |
Dec 31, 2020 | 22.33M | 907.84K | 4.24% |
Dec 31, 2019 | 21.42M | -102.70K | -0.48% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.79B |
Veradigm | 1.53B |
SS Innovations International | 16.04M |
Elite Pharmaceuticals | 71.17M |
Glass House Brands | 188.29M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 21.77M |
Jun An Kang Group | 4.47M |
BioSyent News
- 8 days ago - FAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc. - GlobeNewsWire
- 4 weeks ago - BioSyent Announces Renewal of Normal Course Issuer Bid - GlobeNewsWire
- 7 weeks ago - FAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc. - GlobeNewsWire
- 7 weeks ago - BioSyent reports GAAP EPS of C$0.20, revenue of C$9.56M - Seeking Alpha
- 7 weeks ago - BioSyent Releases Financial Results for Q3 and YTD 2024 - GlobeNewsWire
- 7 weeks ago - BioSyent Declares Fourth Quarter 2024 Dividend - GlobeNewsWire
- 2 months ago - BioSyent Schedules Q3 and YTD 2024 Earnings Release for November 20, 2024 - GlobeNewsWire
- 5 months ago - BioSyent Releases Financial Results for Q2 and H1 2024 - GlobeNewsWire